Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone

Biomaterials

Volumn 35, Issue 13, 2014, Pages 4108-4115

  Holzapfel, Boris M ^a,b   Wagner, Ferdinand ^a,c   Loessner, Daniela ^a   Holzapfel, Nina P ^a   Thibaudeau, Laure ^a   Crawford, Ross ^d   Ling, Ming Tat ^a,e   Clements, Judith A ^a,e   Russell, Pamela J ^a,e   Hutmacher, Dietmar W ^a,f,g  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

^e TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^f GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bone metastasis; Homing; Humanized bone; Osteotropism; Prostate cancer; Tissue engineering

Indexed keywords

BONE METASTASIS; EXTRACELLULAR MATRIX COMPONENTS; HOMING; HUMAN PROSTATE CANCER CELLS; MESENCHYMAL PROGENITOR CELLS; OSTEOTROPISM; PROSTATE CANCERS; TISSUE-ENGINEERED BONES;

BONE; CELLS; COMPUTERIZED TOMOGRAPHY; CYTOLOGY; DISEASES; PATHOLOGY; PHYSIOLOGICAL MODELS; PHYSIOLOGY; TISSUE; TISSUE ENGINEERING;

SCAFFOLDS (BIOLOGY);

LUCIFERASE; RECOMBINANT OSTEOGENIC PROTEIN 1; TISSUE SCAFFOLD;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDITORY OSSICLE; BIOLUMINESCENCE; BONE METASTASIS; BONE STRUCTURE; BONE TRANSPLANTATION; CELL HOMING; CELL PROLIFERATION; CONTROLLED STUDY; CORTICAL BONE; EXTRACELLULAR MATRIX; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL; MICRO-COMPUTED TOMOGRAPHY; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE ENGINEERING; TRABECULAR BONE; BONE TUMOR; COMPLICATION; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; PROSTATE TUMOR; SECONDARY;

ANIMALIA; MURINAE;

BONE NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; TISSUE ENGINEERING; X-RAY MICROTOMOGRAPHY;

EID: 84896728350     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.01.062     Document Type: Article

References (45)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Bubendorf L., Schopfer A., Wagner U., Sauter G., Moch H., Willi N., et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000, 31:578-583.
3. Norgaard M., Jensen A.O., Jacobsen J.B., Cetin K., Fryzek J.P., Sorensen H.T. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). JUrol 2010, 184:162-167.
4. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. JNatl Cancer Inst 2004, 96:879-882.
5. Sturge J., Caley M.P., Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011, 8:357-368.
6. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. NEngl J Med 2004, 351:1502-1512.
7. Seruga B., Ocana A., Tannock I.F. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011, 8:12-23.
8. Shiozawa Y., Pedersen E.A., Havens A.M., Jung Y., Mishra A., Joseph J., et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. JClin Invest 2011, 121:1298-1312.
9. Cleeland C.S., Body J.J., Stopeck A., von Moos R., Fallowfield L., Mathias S.D., et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013, 119:832-838.
10. Rosol T.J., Tannehill-Gregg S.H., LeRoy B.E., Mandl S., Contag C.H. Animal models of bone metastasis. Cancer 2003, 97:748-757.
11. Lawrence M.G., Taylor R.A., Toivanen R., Pedersen J., Norden S., Pook D.W., et al. Apreclinical xenograft model of prostate cancer using human tumors. Nat Protoc 2013, 8:836-848.
12. Rangarajan A., Weinberg R.A. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 2003, 3:952-959.
13. Holzapfel B.M., Thibaudeau L., Hesami P., Taubenberger A., Holzapfel N.P., Mayer-Wagner S., et al. Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. Cancer Metastasis Rev 2013, 32:129-145.
14. Liu S., Goldstein R.H., Scepansky E.M., Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009, 69:8742-8751.
15. Yonou H., Ochiai A., Goya M., Kanomata N., Hokama S., Morozumi M., et al. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate 2004, 58:406-413.
16. Yonou H., Yokose T., Kamijo T., Kanomata N., Hasebe T., Nagai K., et al. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 2001, 61:2177-2182.
17. Hubin F., Humblet C., Belaid Z., Greimers R., Boniver J., Thiry A., et al. Maintenance of functional human cancellous bone and human hematopoiesis in NOD/SCID mice. Cell Transpl 2004, 13:823-831.
18. Kuperwasser C., Dessain S., Bierbaum B.E., Garnet D., Sperandio K., Gauvin G.P., et al. Amouse model of human breast cancer metastasis to human bone. Cancer Res 2005, 65:6130-6138.
19. Murphy W.J., Kumar V., Bennett M. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. JExp Med 1987, 165:1212-1217.
20. Kaplan R.N., Rafii S., Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res 2006, 66:11089-11093.
21. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
22. Wang C., Shen Y. Study on the distribution features of bone metastases in prostate cancer. Nucl Med Commun 2012, 33:379-383.
23. Holzapfel B.M., Chhaya M.P., Melchels F.P., Holzapfel N.P., Prodinger P.M., von Eisenhart-Rothe R., et al. Can bone tissue engineering contribute to therapy concepts after resection of musculoskeletal sarcoma?. Sarcoma 2013, 2013:153640.
24. Holzapfel B.M., Reichert J.C., Schantz J.T., Gbureck U., Rackwitz L., Noth U., et al. How smart do biomaterials need to be? A translational science and clinical point of view. Adv Drug Deliv Rev 2012, 65:581-603.
25. Hutmacher D.W. Biomaterials offer cancer research the third dimension. Nat Mater 2010, 9:90-93.
26. Zaman M.H. The role of engineering approaches in analysing cancer invasion and metastasis. Nat Rev Cancer 2013, 13:596-603.
27. Brown T.D., Slotosch A., Thibaudeau L., Taubenberger A., Loessner D., Vaquette C., et al. Design and fabrication of tubular scaffolds via direct writing in a melt electrospinning mode. Biointerphases 2012, 7:13.
28. Vaquette C., Ivanovski S., Hamlet S.M., Hutmacher D.W. Effect of culture conditions and calcium phosphate coating on ectopic bone formation. Biomaterials 2013, 34:5538-5551.
29. Reichert J.C., Quent V.M., Burke L.J., Stansfield S.H., Clements J.A., Hutmacher D.W. Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials 2010, 31:7928-7936.
30. Singh H., Teoh S.H., Low H.T., Hutmacher D.W. Flow modelling within a scaffold under the influence of uni-axial and bi-axial bioreactor rotation. JBiotechnol 2005, 119:181-196.
31. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979, 17:16-23.
32. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. JBone Miner Res 2010, 25:1468-1486.
33. Haas A.R., Tuan R.S. Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: II. Stimulation by bone morphogenetic protein-2 requires modulation of N-cadherin expression and function. Differentiation 1999, 64:77-89.
34. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006, 38:1310-1315.
35. Moreau J.E., Anderson K., Mauney J.R., Nguyen T., Kaplan D.L., Rosenblatt M. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res 2007, 67:10304-10308.
36. Schuster J., Zhang J., Longo M. Anovel human osteoblast-derived severe combined immunodeficiency mouse model of bone metastasis. JNeurosurg Spine 2006, 4:388-391.
37. Tannous O., Stall A.C., Griffith C., Donaldson C.T., Castellani R.J., Pellegrini V.D. Heterotopic bone formation about the hip undergoes endochondral ossification: a rabbit model. Clin Orthop Relat Res 2013, 471:1584-1592.
38. Moreau J., Anderson K.M., Mauney J.R., Kaplan D., Rosenblatt M. Studies of osteotropism on both sides of the breast cancer-bone interaction. Ann N Y Acad Sci 2007, 1117:328-344.
39. Nemeth J.A., Harb J.F., Barroso U., He Z., Grignon D.J., Cher M.L. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999, 59:1987-1993.
40. Kostenuik P.J., Nguyen H.Q., McCabe J., Warmington K.S., Kurahara C., Sun N., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. JBone Miner Res 2009, 24:182-195.
41. Al Nakouzi N., Bawa O., Le Pape A., Lerondel S., Gaudin C., Opolon P., et al. The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer. Neoplasia 2012, 14:376-387.
42. An Z., Wang X., Geller J., Moossa A.R., Hoffman R.M. Surgical orthotopic implantation allows high lung and lymph node metastatic expression of human prostate carcinoma cell line PC-3 in nude mice. Prostate 1998, 34:169-174.
43. Rembrink K., Romijn J.C., van der Kwast T.H., Rubben H., Schroder F.H. Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate 1997, 31:168-174.
44. Havens A.M., Pedersen E.A., Shiozawa Y., Ying C., Jung Y., Sun Y., et al. An invivo mouse model for human prostate cancer metastasis. Neoplasia 2008, 10:371-380.
45. Clark A.K., Taubenberger A.V., Taylor R.A., Niranjan B., Chea Z.Y., Zotenko E., et al. Abioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials 2013, 34:4777-4785.